NYLIM
KRTX

New York Life Investment Management’s Karuna Therapeutics, Inc. Common Stock KRTX Stock Holding History

New York Life Investment Management’s Portfolio KRTX Stock Details KRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-4,033
Closed -$1.28M – 1573
2023
Q4 		$1.28M Buy
4,033
+245
+6% +$47.6K 0.01% 611
2023
Q3 		$641K Buy
3,788
+2,210
+140% +$416K 0.01% 722
2023
Q2 		$342K Buy
+1,578
New +$338K ﹤0.01% 1180

Other funds holding KRTX

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
S
Sachetta Lynnfield, Massachusetts $206M AUM 26.19% 1-Year Est. Return

New York Life Investment Management's KRTX Position: Q1 2024 in Review

New York Life Investment Management sold out of Karuna Therapeutics, Inc. Common Stock (KRTX) in Q1 2024, closing a stake of 4,033 shares — an estimated $1.28M sold.

New York Life Investment Management first reported a position in KRTX in Q2 2023 and held it in 3 quarters. The position peaked at $1.28M in Q4 2023. 2 funds tracked by Wall St. Rank hold KRTX as of Q1 2024.

  • New York Life Investment Management reported no remaining Karuna Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
  • New York Life Investment Management sold 4,033 Karuna Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $1.28M.
  • New York Life Investment Management first reported a position in Karuna Therapeutics, Inc. Common Stock in Q2 2023 and held it in 3 quarters.
  • New York Life Investment Management's Karuna Therapeutics, Inc. Common Stock position peaked at $1.28M in Q4 2023.
  • 2 funds tracked by Wall St. Rank held Karuna Therapeutics, Inc. Common Stock as of Q1 2024.

Based on New York Life Investment Management's 13F filing for Q1 2024, filed 6 May 2024.